Leukemia supplements最新文献_第5页

Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors. 克拉霉素抑制自噬:提高CML干细胞对酪氨酸激酶抑制剂敏感性的新策略。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.25

A M Carella, G Beltrami, G Catania, G Pica, C Ghiggi, A Garuti, A Carella

引用次数: 6

Minimal residual disease. 残留疾病极少。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.5

D Campana

引用次数: 10

Second-generation TKIs: which and when? 第二代tki:哪代?何时?

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.22

G Saglio

{"title":"Second-generation TKIs: which and when?","authors":"G Saglio","doi":"10.1038/leusup.2012.22","DOIUrl":"https://doi.org/10.1038/leusup.2012.22","url":null,"abstract":"Impressive response rates and good tolerability have led imatinib 400 mg once a day to become the standard frontline therapy for chronic myeloid leukemia (CML) patients. However, approximately one-third of the treated patients do not respond in an optimal manner to this drug, and the appropriate type and rhythm of CML monitoring, as well as the correct action to be undertaken in case of failure or suboptimal responses to imatinib therapy have been published in specific recommendations by European Leukemia Net and National Comprehensive Cancer Network. Failure and also cytogenetic suboptimal responses strongly demand for a change in treatment and for a switch from imatinib to one of the two second-generation tyrosine kinase inhibitors (TKIs) so far registered, dasatinib and nilotinib, for which efficacy as second-line therapy in imatinib-resistant or intolerant cases has been clearly demonstrated in phase II studies, and for which 4-year updates are now available. Other TKIs, at the moment, still under clinical investigation for imatinib-resistant patients include bosutinib and the next-generation TKI ponatinib. Different efficacy and safety criteria characterize each of the mentioned compounds and may help to decide on the one to be preferably used in individual patients. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S40-2"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.22","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34544525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia. 费城染色体阳性急性淋巴细胞白血病的治疗。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.7

O G Ottmann

{"title":"Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.","authors":"O G Ottmann","doi":"10.1038/leusup.2012.7","DOIUrl":"10.1038/leusup.2012.7","url":null,"abstract":"Tyrosine kinase inhibitors (TKIs) directed against the ABL kinase are now used routinely during frontline therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and result in hematologic remission rates exceeding 90%. Minimal residual disease levels are generally lower when TKIs are used in combination with chemotherapy rather than as monotherapy. Although outcome has improved substantially with TKI-based regimens compared with historic controls, allogeneic stem cell transplantation (SCT) in first remission provides the best chance of cure for the majority of patients eligible for SCT. Administration of imatinib after SCT further reduces molecular recurrence and is associated with greatly improved relapse-free and overall survival. The high relapse rate in non-transplanted patients is largely attributable to the emergence of leukemic clones with mutations in the tyrosine kinase domain of BCR-ABL. Ongoing studies with newer TKIs will determine whether these more potent agents are able to sustain remissions without SCT. Assessment of minimal residual disease has become an integral part of the management of Ph+ALL, as it has prognostic importance and is used to guide therapeutic intervention. Novel immunotherapeutic interventions and combinations of TKIs are currently being investigated in clinical trials and may further improve the prognosis of patients with Ph+ALL. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S7-9"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851212/pdf/leusup20127a.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34479559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biology of CML stem cells: the basis for clinical heterogeneity? CML干细胞生物学:临床异质性的基础?

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.23

J M Goldman, M Gordon, A Bazeos, D Marin

引用次数: 3

Antibiotic therapy in hematological neutropenic patients: what is the news? 血液学中性粒细胞减少患者的抗生素治疗:有什么新进展?

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.13

F Pea

引用次数: 0

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. 60岁以上骨髓纤维化患者的同种异体干细胞移植:JAK2抑制剂的可能影响

Leukemia supplements Pub Date : 2012-05-01 Epub Date: 2012-05-09 DOI: 10.1038/leusup.2012.2

V Fauble, J Leis, R A Mesa

{"title":"Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.","authors":"V Fauble, J Leis, R A Mesa","doi":"10.1038/leusup.2012.2","DOIUrl":"https://doi.org/10.1038/leusup.2012.2","url":null,"abstract":"The myeloproliferative neoplasm, myelofibrosis (MF), has only one therapeutic intervention that is potentially curative in these individuals, specifically that of allogeneic stem cell transplantation (ASCT). ASCT has been utilized up to this juncture, primarily in younger individuals with higher risk disease. There is more limited data on outcomes in individuals over the age of 60 years. The choice of an individualized therapeutic intervention for a patient with MF is a very complex issue and is dependent on several factors. The first factor being their overall prognosis with their illness (which can vary from a median of 2 years in high-risk patients to over 10 years in low-risk patients) and the potential impact of a therapeutic intervention not only on survival but also on quality of life. Current available therapies have been strictly palliative for disease-associated anemia and/or splenomegaly. At present, we have a new generation of inhibitors of JAK2 (Ruxolitinib, CYT387, SB1518, TG101348, with others in development), which have been shown to improve splenomegaly, improve symptomatic burden of illness and improve quality of life. In addition, these inhibitors of JAK2 may have an impact on the natural history of MF, but confirmation of the presence and degree of this impact is still pending. Clinical availability of JAK2 inhibitors may alter the timing of transplant in marginal transplant candidates (that is, those over the age of 60), may have a role preceding ASCT to improve spleen size and performance status before transplant and might be frontline therapy in intermediate and high-risk patients who are not candidates for ASCT. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 1","pages":"S2-7"},"PeriodicalIF":0.0,"publicationDate":"2012-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34481278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3